![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Novartis will acquire SanReno's pipeline and capabilities, including the exclusive rights for Greater China and Singapore for two late-stage assets targeting IgAN, ABT-627 (atrasentan), an oral ERA antagonist and zigakibart, a subcutaneously administered monoclonal antibody.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: ABT-627
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 05, 2024